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ABSTRACT 
 
INVESTIGATING THE ROLE OF COILED-COIL DOMAIN CONTAINING 124 
(CCDC124) IN INNATE ANTIVIRAL IMMUNE RESPONSE 
 
ALP ERTUNGA EYÜPOĞLU 
Molecular Biology, Genetics, and Bioengineering 
M.Sc. Thesis, July 2019 
Thesis Supervisor: Tolga Sütlü 
Thesis Co-Supervisor: Meral Yüce 
Keywords: Natural Killer Cells, lentiviral vector, CRISPR, viral transduction 
 
The innate immune system acts as the first line of defense in a non-specific manner 
against infectious diseases as well as malignant transformation. Natural Killer (NK) cells 
are members of innate immune system which are particularly responsible for killing 
virus-infected cells and tumor cells. Distinct properties of NK cells are remarkable in 
terms of cancer immunotherapy. Among several approaches, genetic modification of NK 
cells to enhance their immune function is widely studied with promising results but in 
vitro gene delivery into NK cells is highly challenging. HIV-1 based lentiviral vector 
systems for stable gene transfer have been used in most of the studies that aim genetic 
modification of NK cells. However, viral resistance of NK cells causes low efficiency 
and reduced stability, but enhancement of gene delivery efficiency is possible to achieve 
with small-molecule kinase inhibitors, such as BX795. Stress granule assembly is known 
to be associated with antiviral responses. This study aims to study the effect of CCDC124 
gene which may be associated with stress granule formation and antiviral response during 
lentiviral gene transfer to NK cells. To investigate the mechanism, CRISPR/Cas9 system 
  v 
was used to knock out CCDC124 and other genes that may be involved in the intracellular 
response against lentiviral vectors in HCT116, NK-92 and YTS cell lines. We compared 
the responses of different cell lines to lentiviral transduction and observed significant 
change in transduction efficiencies. Additionally, stress granule formation in CCDC124 
knockout NK-92 cells is examined. Our findings present novel insights into the resistance 
of NK cells to lentiviral gene delivery and provide useful tools to improve genetic 
modification of NK cells. 
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ÖZET 
 
SARILI-SARMAL BÖLGE BULUNDURAN 124 (CCDC124) PROTEİNİNİN 
DOĞAL BAĞIŞIKLIK SİSTEMİNİN ANTİVİRAL YANITINDAKİ ROLÜ 
ALP ERTUNGA EYÜPOĞLU 
Moleküler Biyoloji, Genetik ve Biyomüendislik 
Yüksek Lisans Tezi, Temmuz 2019 
Tez Danışmanı: Tolga Sütlü 
Yardımcı Tez Danışmanı: Meral Yüce 
Anahtar Kelimeler: Doğal öldürücü hücreler, lentiviral vektör, CRISPR, viral 
transdüksiyon 
 
Doğal bağışıklık sistemi, organizmaların enfeksiyonlara ve tümörlere karşı öncül 
bağışıklamaya ihtiyaç duymadan oluşturduğu ilk adım savunma sistemidir. Doğal 
Öldürücü (NK) hücreleri, doğal bağışıklık sisteminin bir elemanı olup özellikle virüsle 
enfekte olmuş hücreleri ve tümörleri hedef alır. NK hücrelerinin özgül yetenekleri kanser 
immünoterapsinde kullanılmak üzere gelecek vaad etmektedir. Pek çok immünoterapi 
yaklaşımı arasından, bağışıklık sistemi hücrelerinde genetik modifikasyon ile bu 
hücrelerin aktivitelerini artırma üzerine çalışmalar yapılmış ve başarılı sonuçlar alınmıştır 
ancak NK hücreleri üzerinde yapılan in vitro genetik modifikasyon denemelerinin başarı 
oranları düşüktür. Bu sebeple NK hücrelerinde stabil gen transferi çalışmaları HIV-1 
bazlı lentiviral vektörler üzerinde yoğunlaşmıştır. NK hücrelerinin virüslere karşı olan 
dirençleri, instabilite ve verimliliğin düşmesine sebep olmaktadır. BX795 gibi küçük 
molekül kinaz inhibitörleri ile yapılan çalışmalarda daha verimli viral transdüksüyon 
sonuçları elde edilebilmiştir. Bu çalışmada hücre içi stres granülleri ile ilişkisi olduğu 
düşünülen CCDC124 geni hedeflenmiş ve viral transdüksiyon sırasındaki antiviral rolü 
araştırılmıştır. Çalışmanın deneysel kısmında CRISPR/Cas9 sistemi kullanılarak 
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HCT116, NK-92 ve YTS hücrelerinde CCDC124 geni ve diğer aday genleri 
susturulmuştur. Geliştirilen hücrelerin lentiviral transdüksiyon sırasındaki davranışları 
incelenmiştir ve lentiviral gen transferi yüzdelerinde önemli değişimler gözlenmiştir. Ek 
olarak CCDC124 geni susturulmuş olan NK-92 hücrelerinde stres granül oluşumuna 
bakılmıştır. Bu çalışmadaki bulgular NK hücrelerinde genetik modifikasyon 
yaklaşımlarının geliştirilmesine ve NK hücrelerinin virüslere karşı direnç 
mekanizmasının anlaşılmasına katkı sağlayacaktır. 
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1. INTRODUCTION 
1.1. Natural Killer Cells 
1.1.1. Innate Immune System Member: NK Cells 
The human body continuously interacts with pathogens through air, food or direct 
contact. These harsh environmental conditions create a necessity for enduring defense 
mechanisms that can protect the body against invading pathogens. The first line of this 
defense is the skin and the mucus surrounding the respiratory system, both of which create 
physical barriers to stop entry of pathogens into the body. However, small pathogens such 
as viruses or microorganisms can find ways to infiltrate into the body. The immune 
system steps in at this point to prevent the host from invasion of pathogenic 
microorganisms. Traditionally, the immune system is studied under two categories: The 
Innate Immune System which acts rapidly and in a non-specific manner and the Adaptive 
Immune System which acts more slowly but has the characteristics of antigen-specificity 
and memory. Cellular components of adaptive immune system, T and B cells, are evolved 
to recognize the pathogen specifically and get activated through the recognition which 
results in proliferation and response against that specific pathogen. Moreover, T and B 
cells can develop immunological memory against pathogens which helps host to respond 
more quickly during a second infection by the same agent (Mulder et al. 2019). Natural 
killer (NK) cells, innate lymphoid cells (ILCs) and phagocytes constitute cellular 
components of the Innate Immune System. 
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Figure 1. Cellular compartments of the immune system 
Particularly, the innate immune system acts as the primary defense mechanism due to 
rapid response time and non-specific activity against a wide range of molecules that are 
common among different pathogens (Alberts et al. 2002). The innate immune system 
does not explicitly recognize the pathogen, but through its cells and receptors, recognizes 
molecular patterns common among pathogens to trigger activation and effector functions. 
Most cells in the immune system later contribute to this response by cytokine production, 
but dendritic cells, macrophages, and natural killer (NK) cells play an essential role as 
members of the innate immune system (Koenderman, Buurman, and Daha 2014) that also 
initiate activation of adaptive immunity.   
1.1.2. Role of NK Cells in Innate Immunity 
NK cells respond against transformed or virally infected cells by inducing target cells to 
undergo apoptosis. The response of NK cells is not antigen-specific, but NK cells track 
major histocompatibility complex class I (MHC-I) molecules on the host cell membrane. 
The MHC-I molecule plays a central role in recognition of target cells by cytotoxic cells 
of the immune system, that is T cells and NK cells. Both T cells and NK cells bind to 
MHC-I molecules, but the outcome of this binding differs dramatically in the two cell 
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types. T cells bind MHC-I via their T Cell Receptor (TCR) as a result of foreign peptide 
presented on MHC-I or foreign MHC molecule and get activated. Unlike T cells, NK 
cells scan self-MHC-I molecule to use the interaction as a regulator of activating and 
inhibitory mechanism. In this way, T cells are trained to recognize pathogens through 
tumor or virus-infected cell-specific antigens, but NK cells are specialized in killing cells 
that have impaired MHC-I molecule, or those have lost MHC-I expression (Sun and 
Lanier 2011). The phenomenon of recognition mechanism that enables NK cells to detect 
MHC-I non-expressing cells called missing-self recognition (Kärre 2008). 
NK cell binding to MHC-I through inhibitory receptors implements self-recognition so 
that healthy cells can escape from cytotoxic activity of NK cells. Therefore, most 
vertebrate cells show high expression of MHC-I on their cell surface. Malignant 
transformation may inherently cause mutations which reduce MHC-I expression and 
enable immune escape from T cell-mediated lysis. Similarly, virus-infected cells may 
show low expression of MHC-I as several viruses have developed mechanisms of MHC-
I downregulation. For example HIV encodes proteins that block MHC-I gene 
transcription, or herpes simplex virus blocks the translocation of the peptide that is 
required for MHC-I formation or cytomegalovirus drags MHC-I into proteasomes for 
degradation (Topham and Hewitt 2009).  In these cases of MHC-I loss in transformed or 
virus-infected cells, NK cells step in to mediate target cell lysis by missing-self 
recognition. 
1.2. NK-92 Cell Line 
1.2.1. Characteristics of NK-92 
NK-92 is a model NK cell line that was derived from a 50-year-old male non-Hodgkin’s 
lymphoma patient in 1992. Proliferation and function of the NK-92 cell line depending 
on the presence of IL-2 in cell culture media and the cell line can survive barely up to 72 
hours without IL-2 stimulation. The expression of CD56 on the cell surface is present 
however they are negative for CD16 expression which is distinct from primary NK cells. 
Detailed examination shows that NK-92 cell line displays functional characteristics of 
induced NK cells (Gong, Maki, and Klingemann 1994). The similarity of NK-92 
functional responses to primary NK cells establishes a promising platform in 
understanding the biology of NK cells.  
  4 
Main consideration in NK cell studies is the source of NK cells, where NK cells constitute 
only 10-15% of circulating blood cells which makes it inconvenient to isolate sufficient 
amount of NK cells. Additionally, ex vivo expansion of NK cells demands multiple 
cytokines which are sometimes supplemented via genetically modified feeder cell lines 
for cost-efficiency concerns, whereas the only requirement is for the NK-92 cell line is 
IL-2. More importantly, the unpredictable risk of graft-versus-host (GvH) reaction in 
allogenic NK transplantation may restrict the studies with primary NK cells whereas the 
more well-defined stable phenotype of NK-92 cells makes them more predictable and 
less susceptible to adverse effects (Klingemann, Boissel, and Toneguzzo 2016). All these 
circumstances put NK-92 cell line as a model in clinical research and clinical trials with 
the NK-92 cell line are ongoing (Hu et al. 2019). 
1.3. Natural Killer Cell-based Cancer Immunotherapy Strategies 
As mentioned above, NK cells are involved in the immune response during cancer and 
microbial infections. As a part of the innate immune system, these effector lymphocytes 
are responsible for restricting tumor growth and spread. NK cells are also able to provide 
indirect cytotoxic functions by cytokine production. While the endogenous NK cells of 
the body try to fight malignancies and infections, failure of these defense mechanisms 
due to the immunosuppressive effect of the tumor is a commonly observed phenomenon. 
In such cases, activation of endogenous NK cells or adoptive transfer of NK cells can be 
used as an approach to boost the anti-tumor NK cell activity. NK cell manipulation studies 
show higher efficiency in anti-tumor response, successful results in organ transplantation, 
and regulation of autoimmune diseases (Vivier et al. 2008). NK cells have been widely 
studied, and there are various approaches developed to induce NK cell function. 
1.3.1. Enhancing Natural Killer Cell Activity with Cytokine Administration 
Interleukins (ILs) are secreted cytokines which regulate immune response by mediating 
growth, differentiation, activation, proliferation, and survival of lymphocytes (T. Jiang, 
Zhou, and Ren 2016). Among these proteins, interleukin-2 (IL-2) has a fundamental role 
in NK cell biology in terms of proliferation and cytotoxicity. IL-2 is a small cytokine that 
is mainly produced by CD4+ T cells. Additionally, CD8+ T cells, NK cells and dendritic 
cells (Zelante et al. 2012) have the potential to secrete IL-2. Functional characteristics of 
IL-2 has significant impact on immune cells such as enhancing cytotoxicity of CD8+ T 
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cells and NK cells, differentiation of T cells and proliferation of NK cells. IL-2 has high 
affinity against its own receptor, when it is formed by its three subunits IL-2Rα (CD25), 
IL-2Rβ (CD122), and IL-2Rγ (CD132). Trimeric formation of IL-2R is found on limited 
group of cells such as activated T cells and Regulatory T cells (Treg) because of IL-2Rα 
expression levels (Liao, Lin, and Leonard 2011). NK cells show high expression of β and 
γ subunits of IL-2 receptor, however extrinsic IL-2 stimulation can trigger α subunit 
expression (T. Jiang, Zhou, and Ren 2016). It is reported that IL-2Rα alone is inefficient 
to induce signal transduction which requires at least dimeric formation of β and γ subunits 
(Abbas et al. 2018; Hodge et al. 2000). 
IL-2 has been applied in the clinic to the patients diagnosed with metastatic renal cell 
carcinoma and metastatic melanoma as monotherapy with good clinical results and tumor 
regression. Promising results led IL-2 to be approved for metastatic renal cell carcinoma 
and metastatic melanoma treatment in 1992 and 1998, respectively. Even though IL-2 
treatment demonstrated tumor regression, side effects such as cytokine storm related to 
the high dose administration of IL-2 and induction of immunosuppressive Tregs in low 
dose IL-2 treated patients diverted studies to combination of IL-2 with other cytokines 
such as IFN-α. Due to cytotoxicity of high dose IL-2, reduced dose IL-2 regimen was 
tested with substitute cytokine combinations, but it did not show significant difference. 
Taken into consideration, potential of IL-2 to trigger immune response would be better 
treatment when it is combined with cell-based therapies (T. Jiang, Zhou, and Ren 2016). 
Recombinant IL-2, known as Proleukin®, has been used in the clinic to boost immune 
system cells against metastatic renal cell carcinoma and metastatic melanoma (Childs and 
Carlsten 2015). Co-administration of ex vivo expanded T cells and IL-2, also shows a 
significant response, but low in vivo survival rates of expanded cells indicates the 
necessity of better ex vivo culture protocols. 
In a similar manner, IL-15, which has therapeutic use in the clinic, plays crucial role in 
NK cell development, survival and activity. IL-15 binds to IL-15Rα with high affinity, 
besides that IL-15 can also bind IL-2Rβ and γ subunits. Due to shared receptor subunits, 
IL-15 and IL-2 show similar functional properties. Additionally, IL-15 has its own 
distinct immunoregulatory properties as well. IL-15 is a 15 kDa protein which is secreted 
by monocytes, macrophages, dendritic cells, fibroblasts, bone marrow stromal cells, and 
nerve cells constitutively (Waldmann and Tagaya 2002; Perera et al. 2012). IL-15 has a 
vital role in cytokine expression and cytotoxic activity of NK cells. IL-15-induced NK 
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cells show higher cytolytic activity via upregulation of activator receptor NKG2D (C. 
Zhang et al. 2008). 
As a cytokine regulator, IL-15 induces expression of IFN-γ, TNF-α, and GM-CSF in NK 
cells when combined with IL-12. IL-15 dysfunction or failure in expression is associated 
with viral infection-related diseases which are directly related to NK cell participation in 
antiviral defense mechanism. A study on a patient who lacks NK cell activity shows that 
NK cell deficiency constitutes sensitivity against herpesvirus (Biron, Byron, and Sullivan 
1989). Similarly, IL-15 expression is one of the targets of HIV-1 infection. After viral 
infection, inflammatory cytokine expression increases by various cell types such as NK 
cells, dendritic cells, and T cells. Upregulated cytokine levels increase CD4+ T 
susceptibility to HIV (Manganaro et al. 2018) and disease progression causes CD4+ T cell 
death and disorder in T cell, B cell, and NK cell function. Likewise, disrupted IL-15 
expression leads to reduced NK cell development and proliferation. These findings 
suggest that IL-15 has a great potential to reconstitute NK cell activity during viral 
infection or cancer disease. On the other hand, IL-15 stimulation of HIV infected CD4+ 
T cells would enhance viral replication and cause disease progression. Although the 
promising results of cytokine use as therapeutic agent, it has crucial restrictions and other 
approaches emerged for cancer immunotherapy (Perera et al. 2012). 
1.3.2. IMiD-induced NK Cell Proliferation and Activation 
A chemical compound, thalidomide, was discovered in the 1950s to cure nausea in 
pregnancy which was later used as an angiogenesis inhibitor. In the late 50s, severe birth 
defects were identified on the babies whose mothers used thalidomide treatment during 
the pregnancy. This is also known as Thalidomide Syndrome. These events lead 
researchers to study molecular mechanism of thalidomide and potential effect on 
angiogenesis (Vargesson 2013). Along with the effect on angiogenesis, research on 
Thalidomide revealed several immunomodulatory functions of Thalidomide, particularly 
in inducing cytokine production. Thalidomide and related immunomodulatory drugs 
(IMiDs), which are thalidomide derivatives, pomalidomide (Pomalyst/Imnovid®) and 
lenalidomide (Revlimid®), have been widely studied and demonstrated as indirect NK 
cell activity enhancers. The immunomodulatory mechanism of IMiDs is explained as a 
co-stimulatory signal to T cells to enhance proliferation and induce IL-2 and IFN-γ 
secretion (Anderson 2005; Davies et al. 2001; Haslett et al. 1998). Molecular mechanism 
  7 
of thalidomide and derivatives are still being studied and not fully understood. Even so, 
successful results have been reported for both anti-angiogenic effect and 
immunomodulatory function on the patients who are diagnosed with multiple myeloma 
(Quach et al. 2010). However, preclinical outcomes are restricted in clinical practice 
because of the challenging characteristics of cancer disease and IMiDs still need to be 
studied in detail and improved. 
1.3.3. Retargeting NK cells Against Tumors via Monoclonal Antibodies (mAbs) 
The use of antibodies or engineered proteins in targeted cancer immunotherapy has been 
an emerging research topic for several years (Mayes, Hance, and Hoos 2018). Tumor-
targeted monoclonal antibodies (mAbs) with higher affinity have increased the success 
rates of cancer treatment strategies (Adler and Dimitrov 2012). The primary role of mAbs 
is targeting the tumor directly to kill or indirectly to suppress tumor growth. mAb 
treatments enable antigen-specific interactions with host immune system components to 
induce or reactivate immune responses (Childs and Carlsten 2015). More specifically, 
antibody-coated target cells are destroyed in a process called Antibody-Dependent Cell-
mediated Cytotoxicity (ADCC) in which NK cells play a significant role. 
 
Figure 2. Antibody-Dependent Cell-mediated Cytotoxicity 
Identification of ADCC was first given by Erna Möller in 1965 as Contact-induced 
Cytotoxicity by Lymphoid Cells (MOELLER 1965). The description demonstrates the 
effect of rabbit antiserum on lymphoid cells, which lead cells to accumulate around the 
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tumor. Further studies revealed that immunoglobulin content of the antiserum is the factor 
that activates immune cells and directs them to tumor region (MacLennan, Loewi, and 
Harding 1970). It is known that Fc receptors for immunoglobulin G (IgG) are presented 
on immune cells (Adler and Dimitrov 2012).  
FcγR family is composed of four classes, and human NK cells express two among these 
four types. NK cells do not express the inhibitor FcγR so that the significance of NK cells 
in ADCC depends on the two forms, FcγRIIC (CD32c) and FcγRIIIA (CD16a) which 
have roles on starting signal transduction of NK cell-activating pathways upon binding 
Fc portions of the antibodies bound to the surface of the target cell. Current mAb therapies 
in clinical use mediate most of their ADCC effects through mainly NK cells and the other 
FcR expressing immune cells such as macrophages. Examples include Rituxan® 
(rituximab) and Erbitux® (cetuximab) which are targeted to CD20 and EGFR, 
respectively, as well as several other studies with other mAbs that demonstrate higher NK 
cell activity, such as Herceptin® (trastuzumab) (Alderson and Sondel 2011), GAZYVA® 
(obinutuzumab) and anti-GD2 mAb (Wang et al. 2015). 
1.3.4. Genetic Manipulation of NK cells for Cancer Immunotherapy 
NK cell cytotoxicity is mediated by activating and inhibitory receptors that are present 
on the membrane of NK cells without any prior stimulation (Pegram et al. 2011). In terms 
of cancer immunotherapy, NK cell function depends on the interaction between effector 
NK cells and tumor cells (Sun and Lanier 2011). However, during cancer development, 
impairments in the metabolism of the tumor microenvironment (TME) causes 
accumulation of immunosuppressive factors leading to inhibition of NK cells among 
other effector populations of the immune system. Emerging applications in NK cell 
genetic manipulation to let NK cells escape from immunosuppression consist of various 
approaches for enhancing persistence or cytotoxic activity (Chambers, Lupo, and 
Matosevic 2018). Early studies aiming to genetically modify NK cells are applied to 
enhance persistence via endogenous cytokine expression. As it is mentioned in previous 
part, IL-2 has a vital role in NK cell survival and proliferation. It is also demonstrated 
that systemic IL-2 administration may have adverse clinical side effects, for that matter 
stable endogenous gene expression gained importance in immunotherapeutic approaches. 
First endogenously IL-2 expressing NK cells are achieved by Miller et al. in 1997 by 
retroviral transduction. Despite the challenges in determining experimental procedures, 
  9 
they optimized the retroviral transduction protocol to successfully obtain IL-2 expressing 
NK cells and reported proliferation for 7 days after IL-2 withdrawal (J. S. Miller et al. 
1997). A similar study with different protocol on NK-92 and YT cell lines also indicates 
the potential of NK cell-based cytokine gene therapy with Nagashima et al. reporting 
exogenous IL-2 independent proliferation for more than 5 months and enhanced cytotoxic 
activity in vivo (Nagashima et al. 1998).  
For non-viral genetic modification of NK cells, Grund et al. demonstrated DNA 
electroporation application on the NK-92 cell line. This study reports optimal conditions 
for NK cell modification via electroporation method (Grund and Muise-Helmericks 
2005) for transfer of the EGFP gene. Further studies that are inspired by electroporation 
showed successful genetic manipulation of various NK cell lines. A study with NKL cell 
line shows IL-15 gene delivery with electroporation. Their findings suggest that 
transfected IL-15 gene is expressed stably and they observed improved proliferation and 
reduced apoptotic cells with enhanced in vitro cytotoxic activity against human 
hepatocellular carcinoma (W. Jiang, Zhang, and Tian 2008). Although the improvements 
on electroporation transfection in several approaches (Carlsten et al. 2014; Boissel et al. 
2009) have been stated, the challenges of the technique restrict its clinical use. Most 
concerning limitation in transfection via electroporation is cell death during the primary 
electric pulse. Electroporation induced cell death decreases the efficiency or even leaves 
the method completely non-functional (Piñero et al. 1997). Likewise, different 
approaches such as nucleofection (D. Zhang et al. 2015), lipofection (Regis et al. 2017) 
and trogocytosis (Cho et al. 2014) have been examined to non-virally modify NK cell 
genome. However, standardized protocols needed for each technique remain as the main 
consideration (Matosevic 2018). Taking into account the gene delivery efficiency and 
clinical efficacy of genetically modified cells, the use of retroviral or lentiviral vectors 
for gene delivery are currently most common for genetic modification of NK cells. These 
will be covered in the next chapter of this thesis. 
Recent studies with genetically modified (GM) NK cells are focused on chimeric antigen 
receptor (CAR) gene delivery to trigger recognition of target cell and redirect cytotoxic 
activity against a specific cell surface antigen found on the tumor cells. Müller et al. used 
NK-92 cell line to generate CD20 specific effector cells against B cell lymphomas and 
reported specificity cytotoxic activity of retrovirally transduced NK cells against only 
CD20 expressing cells (Müller et al. 2008). Another study with primary NK cells was 
  10 
aimed to generate chronic lymphocytic leukemia (CLL) and Raji targeting NK cells via 
the use of a CD19-targeted CAR and reported high efficacy, both in vitro and in vivo of 
GM NK cells (Liu et al. 2018). Similar studies have reported promising results (Yvon et 
al. 2017; Velasquez et al. 2016), but limitations in retroviral gene delivery and 
development of lentiviral vector technologies have in the last two decades shifted the 
focus more on lentiviral gene delivery. 
Similarly to retroviral studies, there are increasing numbers of studies with lentiviral 
vectors to develop CAR-expressing NK cells (Steinbach et al. 2014; Kobayashi et al. 
2014). Our group and others have also recently used lentiviral vectors to express 
functional TCR complexes on NK cell lines and enable for the first time the targeting of 
intracellular antigens by NK cells (Mensali et al. 2019; Parlar et al. 2019). Although 
applications vary, and viral vectors seem to outperform non-viral approaches, the 
common denominator in genetic modification studies remains that the overall gene 
delivery in NK cells remains relatively low. A study with primary NK cells to set several 
lentiviral transduction parameters shows no relation between lentiviral transduction and 
functional properties of NK cells, though challenges remain problematic in lentiviral gene 
delivery (Carlsten and Childs 2015; Micucci et al. 2006). 
1.4. Lentiviral Vectors 
Lentiviruses are HIV-based viruses which are a subclass of the retroviridae family 
(Naldini, Blömer, et al. 1996). Lentiviral vectors derived from these viruses have become 
efficient tools in gene therapy. Recent challenges in gene therapy and other vector 
systems exhibit increasing demand for engineered lentiviral vectors. Especially, distinct 
properties of lentiviral systems such as the potential to transduce a large variety of 
dividing and non-dividing cells with stable transgene expression prove their importance.  
1.4.1. Life Cycle of a Lentivirus 
To better understand the underlying mechanism of lentiviral vector systems, an 
examination of the life cycle of a retrovirus is of paramount importance. Viral integration 
begins with attachment of the infectious particle to the target cell by connection between 
the envelope glycoprotein and cell surface receptors. When binding is achieved, viral 
envelope fuses with the target cell membrane which results in the release of the virion 
into the target cell cytoplasm. The capsid gets uncoated, and through reverse 
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transcription, single-stranded viral RNA (ssRNA) is converted into double-stranded DNA 
(dsDNA) and transported into the nucleus. The transport to the nucleus is maintained by 
a pre-integration complex that can facilitate active transport into the nucleus in 
lentiviruses such as HIV-1 while gammaretroviruses lack this active transport 
mechanism. This difference is critical since gammaretroviruses must wait for the cell 
cycle to proceed for access into the nucleus during prophase where the nuclear envelope 
breaks down. When viral DNA is integrated into cell genome, expression of viral genes 
begin. Viral ssRNA and proteins get enfolded and form virus particle proximal to the cell 
membrane where new viral particles bud off the infected cell (Buchschacher and Wong-
Staal 2000; Escors and Breckpot 2010). 
 
Figure 3. Life cycle of a retrovirus 
1.4.2. Development of Lentiviral Vectors 
Several restrictions and safety concerns discovered by the early adapters of retroviral 
systems lead the development of safer and more efficient lentiviral vectors based on HIV-
1. Lentiviral vectors are significantly distinct from retroviral vectors in their ability to 
transduce non-dividing cells as they have the potential to actively transport into the 
nucleus. This leads to a relatively safer integration profile for lentiviral vectors (Milone 
and O’Doherty 2018; Cooray, Howe, and Thrasher 2012). Lentiviral vectors are 
Binding Fusion 
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Translation 
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developed and explained in three generations. First-generation lentiviral vectors consist 
of two constructs; packaging plasmid and the vector containing gene of interest. 
Packaging plasmid in this system includes most of HIV genes (including the envelope 
gene) but lacks packaging signal (ψ). Therefore, this plasmid alone is deficient for viral 
particle production. Moreover, plasmid contains cytomegalovirus (CMV) promoter and 
polyadenylation site at 5’ and 3’ ends instead of long terminal repeats (LTR). For second-
generation vectors, furface glycoprotein of vesicular stomatitis virus (VSV-G) is encoded 
on a separate plasmid as the envelope plasmid and third vector contains target gene with 
required genes for packaging and reverse transcription (Naldini, Blomer, et al. 1996).  
A) 
 
B) 
 
C) 
 
Figure 4. Development of lentiviral vectors. (A) First-generation lentiviral 
vectors, (B) Second generation lentiviral vectors, (C) Third generation 
lentiviral vectors 
Further studies with HIV-based lentiviral vectors has revealed that elimination of 
accessory proteins does not interfere with transduction efficiency (Gruber et al. 2000). 
Later, it is understood that accessory genes have a role in survival in vivo but do not 
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participate in viral replication where regulatory genes fulfill the requirement (Milone and 
O’Doherty 2018). In accordance with these findings, second-generation lentiviral vectors 
are developed lacking Vip, Vpr, Vpu and Nef genes (Zufferey et al. 1997). For next 
version, safety concerns are prioritized for development of vectors. In third-generation 
lentiviral vectors, gag/pol and rev genes are encoded on separate plasmids which creates 
a requirement for three necessary constructs for packaging. Utilization of engineered 
LTRs in this version leaves tat gene dysfunctional so that third generation vectors do not 
include tat gene. Further safety improvements are applied on the 3’LTR by by disruption 
of the U3 region, which provides a self-inactivation function (Breckpot, Aerts, and 
Thielemans 2007; Milone and O’Doherty 2018). 
1.5. Innate Antiviral Defense Mechanism 
1.5.1. Innate Pattern Recognition System 
Innate immune system members are evolved to generate rapid response against pathogens 
without antigen specificity. The interaction signals between host and pathogen are 
received by pathogen-recognition receptors (PRRs), which regulate recognition through 
pathogen-associated molecular patterns (PAMPs) (Kumar, Kawai, and Akira 2011a). 
Unlike the antigen-specific adaptive immune system components; conserved molecular 
patterns activate innate immune response via general carbohydrates, lipoproteins or 
nucleic acids (Kumar, Kawai, and Akira 2011a). PRR induced activation results in 
upregulated cytokine production, mainly interferons and inflammatory cytokines. 
Identified PRRs are divided into five groups which are Toll-like receptors (TLRs), C-type 
lectin receptors (CLRs), RIG-I-like receptors (RLRs), nucleotide oligomerization 
domain-like receptors (NOD-like/NLRs) and AIM2-like receptors (ALRs) (Brubaker et 
al. 2015). Some of these receptors are involved in viral component recognition to generate 
antiviral innate immunity.  
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Table 1. Recognition of viral RNA by PRRs 
Pattern Recognition Receptors (PRRs) Involved in Viral Infections 
Endosomal Recognition Cytosolic Recognition 
Toll-Like Receptor Family 
(TLRs) 
RIG-I Like Receptor Family 
(RLRs) 
TLR3 TLR7 TLR8 TLR9 DDX58 
(RIG-I) 
IFIH1 
(MDA5) 
LGP2 
Viral 
dsRNA 
Viral ssRNA CpG 
DNA 
Short 
dsRNA 
Long 
dsRNA 
Regulatory 
Type 1 IFN and proinflammatory cytokine expression 
 
1.5.2. Antiviral Innate Immune Response via Stress Granule Formation  
Among many PRRs, TLRs are widely studied receptors that have roles against several 
types of microorganisms. Human TLRs are divided into ten subclasses with different 
targets. TLR1, 2, 4, 5 and 6 are transmembrane proteins to recognize usually glycoprotein 
or lipid-based PAMPs, on the other hand, TLR3, 7, 8 and 9 are endosome located for 
nucleic acid targets (Kumar, Kawai, and Akira 2011b). TLR9 is responsible for sensing 
viral DNA that contains unmethylated CpG motifs which are typically found in herpes 
simplex virus (HSV) and murine cytomegalovirus (MCMV) genome. The recognition of 
viral DNA by TLR9 leads to recruitment of the adaptor protein, MyD88, to induce 
downstream of its signaling pathway where NF-κB gets activated and upregulates Type I 
IFN and inflammatory cytokines such as TNF-α expression (Wagner 2009). TLR7/8 also 
trigger the same cascade of signaling pathway by sensing viral ssRNA of RNA viruses 
(Akira and Hemmi n.d.). TLR3 is assigned to recognize Polyinosinic:polycytidylic acid 
(poly I:C) which has similar structural properties with dsRNA also known as the synthetic 
analog of dsRNA. Binding of TLR3 to poly I:C leads to recruitment of TRIF adaptor 
protein that induces NF-κB activation and results in upregulation of Type I IFN and 
inflammatory cytokines such as TNF-α expression (Kumar, Kawai, and Akira 2009). 
Some intracellular PRRs have the same responsibility as endosomal TLRs, but they patrol 
the cytoplasm instead of the endosome. RLRs participate in cytoplasmic recognition of 
PAMPs. RLR family is composed of three identified proteins, RIG-I, IFIH1 and LGP2 
(Bruns and Horvath 2014). Retinoic acid-inducible gene I (RIG-I) is able to recognize 
viral nucleic acids through the 5′-triphosphorylated uncapped viral ssRNA. Healthy host 
cells carry capped ssRNA so RIG-I can distinguish host and viral nucleic acids 
(Thompson et al. 2011). Even though MDA5 mechanism has not been identified, different 
  15 
form RIG-I, MDA5 recognizes larger fragments of viral RNA with lower affinity (Bruns 
and Horvath 2014). LGP-2 is considered to be associated with MDA5 recognition to assist 
MDA5 binding (Rodriguez, Bruns, and Horvath 2014). As a result of RIG-I and viral 
RNA interaction, RIG-I recruits IPS-1 which is followed by induction of TBK1 that 
phosphorylates IRF-3 and IRF-7 transcription factors for the Type I IFN expression (Kato 
et al. 2006). The third component of the RLR family, LGP2 acts as a mediator of RLR 
related viral RNA recognition and antiviral response. Both inhibitory roles in knockout 
mice and activator roles synergic to MDA5 of LGP2 have been reported but need to be 
further investigated (Bruns and Horvath 2014).  
Cellular restriction factors also participate in intracellular recognition of viral compounds. 
These factors are expressed constitutively in a number of cell types and contain 
recognition motifs against viral components (Blanco-Melo, Venkatesh, and Bieniasz 
2012). Among cellular restriction factors, several members of the tripartite motif (TRIM) 
family carry out antiviral activity. TRIM protein activity is defined by structural features 
that follow N-terminal RING E3 ligase domain, one or two B-box domains, and a coiled-
coil domain. Especially α isoform of TRIM5 gene recognizes viral capsid proteins and 
acts as restrictor of viral replication or inhibitor of viral infection (Colomer-Lluch et al. 
2018). 
Detection of viral nucleic acids in the cytoplasm also induces several other pathways such 
as apoptosis (Danthi 2016) or stress granule formation (Onomoto et al. 2014). Stress 
granules, a type of membrane-less organelles, are dense cytoplasmic foci which are 
clustered untranslated messenger ribonucleoproteins (mRNPs). Stress granule formation 
takes place under stress conditions, for example during viral infections (Protter and Parker 
2016b). Mass spectrometry analysis has revealed some components of stress granules that 
are mainly RNA-binding proteins (RBPs) (Jain et al. 2016). (Protter and Parker 2016c). 
Numerous viruses are reported as inducers of stress granule formation by activating 
RNA-dependent protein kinase (PKR) and eukaryotic initiation factor (eIF) kinases 
(Onomoto et al. 2014). PKR activation is demonstrated by the interaction between PKR 
and ssRNA (Mayo and Cole 2017) or dsRNA (Lemaire et al. 2008a). Additionally, PKR 
activation can be induced by IFN stimulation (Pindel and Sadler 2011) which is a result 
of upregulated expression levels of IFN during viral inflammation (Onomoto et al. 
2012a). In consequence of viral infection, activated PKR leads to eIF2α phosphorylation 
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(Lemaire et al. 2008b) and inhibits viral translation inhibition via stress granule formation 
(Onomoto et al. 2012b). 
1.5.3. Possible Role of CCDC124 in Antiviral Response Through Stress Granules 
Non-RNA-binding proteins such as translation initiation factors and RNA-binding 
proteins constitute the stress granule assembly (C. L. Miller 2011). RasGAP-SH3-binding 
protein (G3BP) is identified as an RNA-binding protein with two isoforms G3BP1 and 
G3BP2 (Tourrière et al. 2003). Direct relation of G3BP1 in stress granule formation is 
reported in multiple studies and is used as a stress granule marker (McCormick and 
Khaperskyy 2017). Other RNA-binding proteins that are prominent in stress granules, T-
cell intracellular antigen 1 (TIA-1) and TIA-1-related protein (TIAR) together with G3BP 
have common features called intrinsically disordered regions (IDR) (Protter and Parker 
2016a). According to structural analysis and classification of IDRs, some of the IDRs 
contain coiled-coil based complexes (van der Lee et al. 2014). The coiled-coil domains 
(CCDs) are motifs found in proteins that have a crucial role in cellular structure and signal 
transduction of eukaryotic cells (Li et al. 2016). One of the members of this family and 
recently characterized Coiled-coil domain containing 124 (CCDC124) gene is conserved 
in most species. Localization of CCDC124 in centrosome during cell division has been 
demonstrated without dependency to centrosome formation. However, absence of 
CCDC124 causes impaired cytokinesis which results with multinucleated cells. It has 
been reported that CCDC124 plays a role in cytokinesis by interacting with Ras-guanine-
nucleotide exchange factors 1b (RasGEF1b) (Telkoparan et al. 2013). As mentioned 
previously, Toll-like receptor 3 (TLR3) is one of the TLR family members which is 
responsible for viral RNA recognition, mostly found in intracellular compartments, such 
as endoplasmic reticulum (ER), lysosomes or endosomes (Jensen and Thomsen 2012). 
TLR induced upregulation in expression of RasGEF1b and localization in early 
endosomes is demonstrated in murine macrophages (Andrade et al. 2010). Similar to 
RasGEF1b, it is also confirmed that TLR3 localizes to early endosomes (Funami et al. 
2007). The interaction between TLR3 and RasGEF1b is still unidentified.  
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2. AIM OF THE STUDY 
Natural killer cells are known to be resistant against lentiviral gene delivery. NK cells 
provide the first line of host protection mechanism, especially against viral threats. The 
recognition is not antigen-specific; instead, NK cells utilize specific intracellular patterns 
to detect the pathogen and respond to infection. This defense mechanism in primary NK 
cells is also seen in the NK-92 cell line which hinders the efficiency of gene delivery to 
NK cells using lentiviral vectors. To overcome this issue, small kinase inhibitors have 
been adapted to viral transduction methods to increase viral transduction efficiencies. The 
use of BX795, targeted to TBK1/IKKε pathway, during lentiviral transduction have been 
shown previously as transduction efficiency enhancer in NK-92 cell line and primary 
human NK cells (Sutlu et al. 2012). Our previous studies also confirm the enhancer effect 
of (5Z)-7-Oxozeaenol (OXO) which is targeted to MAPKK pathway. However, critical 
mediators of innate antiviral pathways have not been clarified yet.  
Lentiviruses vary from retroviruses in their ability to integrate into non-dividing cells. 
However, intracellular dynamics during cytokinesis still have an impact on lentiviral gene 
delivery. Even though lentiviruses have been known to be able to deliver their gene into 
non-dividing cells, higher transduction efficiencies have been shown during G2 phase of 
the cell cycle (S. Zhang et al. 2006). These findings suggest that lentiviral transduction 
would be reduced in cells with impaired cytokinesis. CCDC124 protein has been 
identified as an agent that participates in cytokinesis by localizing in centrosomes. 
CCDC124 knockout cells have shown inability to divide and return to G1 phase. As a 
result of cytokinesis role, we considered that CCDC124 absence would have a proviral 
effect on the innate immune response. 
On the other hand, stress granules have been reported as inhibitor of viral infections and 
viral replication. Our next consideration is the potential role of CCDC124 in stress 
granule formation because of its possible interaction with stress granule components. The 
aim of this study is to reveal the mechanism of CCDC124 in innate antiviral response by 
investigating lentiviral transduction efficiencies in CCDC124 knockout cell lines. 
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3. MATERIALS AND METHODS    
3.1. Materials  
3.1.1. Chemicals 
Table 2. List of chemicals 
Chemicals and Media Components Company 
(5Z)-7-Oxozeaenol Sigma, Germany 
2-Mercaptoethanol Sigma, Germany 
Agar Sigma, Germany 
Agarose Sigma, Germany 
Ampicillin Sodium Salt  CellGro, USA 
Boric Acid Sigma, Germany 
Bovine Serum Albumin neoFroxx, Germany 
BX795  Sigma, Germany 
Chloroquine Sigma, Germany 
Distilled Water Merck Millipore, USA 
DMEM  GIBCO, USA 
DMSO  Sigma, Germany 
DNA Gel Loading Dye, 6X  NEB, USA 
DPBS Sigma, Germany 
EDTA  Applichem, Germany 
Ethanol Sigma, Germany 
Ethidium Bromide  Sigma, Germany 
Fetal Bovine Serum  Thermo Fischer Scientific, USA 
HEPES Solution, 1 M  Sigma, Germany 
Hoechst 33342 Solution (20 mM) Thermo Fischer Scientific, USA 
Interleukin-2  Proleukin, Novartis 
Isopropanol  Sigma, Germany 
LB Broth Sigma, Germany 
L-glutamine, 200 mM Thermo Fischer Scientific, USA 
MEM Non-Essential Amino Acid Solution  Thermo Fischer Scientific, USA 
MEM Vitamin Solution, 100X Thermo Fischer Scientific, USA 
Methanol  Sigma, Germany 
Mowiol Mounting Medium Sigma, Germany 
NaCl Sigma, Germany 
RNAase A Thermo Fischer Scientific, USA 
PIPES  Sigma, Germany 
Poly-L-lysine Sigma, Germany 
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Protamine Sulfate  GIBCO, USA 
RPMI 1640  GIBCO, USA 
Triton X-100  Sigma, Germany 
Sodium Pyruvate Solution, 100 mM  GIBCO, USA 
Trypsin-EDTA GIBCO, USA 
3.1.2. Equipment 
Table 3. List of equipment 
Equipment Company 
Autoclave  Hirayama, HiClave HV-110, Japan 
Balance ISOLAB, 302.31.002, Germany 
Centrifuge Eppendorf, 5415D, Germany 
Eppendorf, 5702, Germany 
VWR, MegaStar 3.0R, USA 
Beckman Coulter, Allegra X-15R, USA 
CO2 Incubator Thermo Fisher, Heracell Vios 160i, USA 
Binder, Germany 
Deep Freezer -80 oC, Forma, Thermo ElectronCorp., USA 
-20 oC, Bosch, Turkey 
Electrophoresis Apparatus Biorad Inc., USA 
Filters (0.22 mm and 0.45mm) Merck Millipore, USA 
Flow cytometer BD LSR Fortessa, USA 
Freezing Container Mr. Frosty, Thermo Fischer Scientific, USA 
Gel Documentation Biorad, UV-Transilluminator 2000, USA 
Hemocytometer ISOLAB, Neubauer, 075.03.001, Germany 
Ice Machine Scotsman Inc., AF20, USA 
Laminar Flow Heraeus, HeraSafe HS 12, Germany 
Heraeus, HeraSafe KS, Germany 
LightCycler® 480 Roche, Switzerland 
Liquid Nitrogen Tank Taylor-Wharton, 300RS, USA 
Magnetic Stirrer VELP Scientifica, Italy 
Microliter Pipettes Gilson, Pipetman, France 
ISOLAB, Germany 
Thermo Fisher Scientific, USA 
Microscope Zeiss, Primo Vert, Germany 
Zeiss Observer Z1, Germany 
Zeiss Confocal LSM 880, Germany 
Microwave Oven Bosch, Turkey 
pH Meter Mettler Toledo, USA 
Refrigerator Bosch, Turkey 
Shaker Incubator New Brunswick Sci., Innova 4330, USA 
Spectrophotometer New Brunswick Sci., USA 
NanoDrop 2000, Thermo Fischer Scientific, 
USA 
Thermocycler C1000 Touch, Biorad, USA 
Eppendorf, Mastercycler, Germany 
PTC-200, MJ Research Inc., Canada 
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3.1.3. Buffers and Solutions 
Agarose Gel: For 100 ml 1% w/v gel, 1 g of agarose powder was dissolved in 100 ml 
0.5X TBE buffer by heating. 0.01% (v/v) ethidium bromide was added to the solution. 
Blocking Solution: For 50 mL solution, 1 g BSA was dissolved in 50 mL PBS-T. 
Calcium Chloride (CaCl2) Solution: 60 mM CaCl2 (diluted from 1 M stock), 15% 
Glycerol, 10 mM PIPES (pH 7.00) were mixed and sterilized by autoclaving at 121oC for 
15 minutes and stored at 4oC. 
DAPI Solution: For DAPI solution, 1:100.000 dilution of DAPI dye was prepared in 
blocking solution 
HBS Solution (2X): 280 mM NaCl, 50 mM HEPES and 1.5 mM Na2HPO4 were mixed 
and pH was adjusted to 7.1 with 10 M NaOH and sterilized by filtering with 0.22 µm 
filter and stored at -20oC 
Phosphate-buffered saline (PBS): For 1000 ml 1X solution, 100 ml 10X DPBS was added 
to 900 ml ddH2O and the solution was filter-sterilized. 
PBS-T: For 50 mL solution, 50 µL of Triton X-100 was filled up to 50 mL with 1X PBS. 
PI Solution: 0.5 µg of PI stain was dissolved in 100µl in PBS. 
Tris-Borate-EDTA (TBE) Buffer: For 1 L 5X stock solution, 54 g Tris-base, 27.5 g boric 
acid, and 20 ml 0.5M EDTA (pH 8.00) were dissolved in 1 L of ddH2O. The solution is 
stored at room temperature (RT) and diluted 1 to 10 with ddH2O for working solution of 
0.5X TBE. 
3.1.4. Growth Media 
Luria Broth (LB): For 1 L 1X LB media, 20 g LB powder was dissolved in 1 L ddH2O 
and then autoclaved at 121°C for 15 minutes. For selection, kanamycin at a final 
concentration of 50 μg/ml or ampicillin at a final concentration of 100 μg/ml was added 
to liquid medium just before use. 
LB-Agar: For 1X agar medium in 1L, 20 g LB powder and 15 g bacterial agar powder 
were dissolved in 1 L ddH2O and then autoclaved at 121°C for 15 minutes. Then, 
autoclaved LB agar is mixed with antibiotic of interest at the desired ratio. Kanamycin at 
a final concentration of 50 μg/ml or ampicillin at a final concentration of 100 μg/ml was 
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added to prepared medium just before pouring into sterile Petri dishes. Sterile agar plates 
were kept at 4°C. 
DMEM: 293T, 293FT, and HCT116 cells were maintained in culture in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-Glutamine, 1mM 
Sodium Pyruvate, 0.1mM MEM Non-essential amino acid solution, and 25mM HEPES 
solution. 
RPMI: NK-92 and YTS cell lines were maintained in culture in RPMI1640 supplemented 
with 20% heat-inactivated fetal bovine serum, 25 mM HEPES, 2 mM L-Glutamine, 1X 
MEM vitamins, 0.1 mM MEM Non-essential amino acid solution, 1 mM Sodium 
Pyruvate, and 0.1 mM 2-mercaptoethanol. For the NK-92 cell line, 1000 U/ml 
Interleukin-2 was added to culture every 48 hours. 
Freezing medium: All the cell lines were frozen in heat-inactivated fetal bovine serum 
containing 6% DMSO (v/v). 
3.1.5. Commercial Kits 
Table 4. Commercial kits 
Commercial Kit Company 
LightCycler® 480 SYBR Green I 
Master Kit 
Fermentas, USA 
Nucleo Spin® Plasmid Midiprep Kit Macherey-Nagel, USA 
RNA isolation kit Zymo Research, USA 
RvertAid First Strand cDNA 
Synthesis Kit 
Thermo Fisher, USA 
Taq DNA Polymerase with Standard 
Taq (Mg-free) Buffer Kit 
NEB, USA 
3.1.6. Enzymes 
All the restriction enzymes, polymerases and PCR reaction supplements are obtained 
from either Fermentas or New England Biolabs. 
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3.1.7. Antibodies 
Table 5. List of antibodies 
Antibody Company 
Anti-G3BP1 (ab56574) Abcam, UK 
Anti-mouse IgG (H+L), F(ab')2 
Fragment (Alexa Fluor ® 594 
Conjugate) 
CST, The Netherlands 
Anti-rabbit IgG (H+L), F(ab')2 
Fragment (Alexa Fluor® 488 
Conjugate) 
CST, The Netherlands 
CCDC124 Antibody, A301-835A Bethyl Lab, USA 
Mouse APC anti-CD56 (NCAM 16.2)  BD Biosciences, USA 
3.1.8. Bacterial Strains 
Top10 strain is used for lentiviral construct amplifications. 
3.1.9. Mammalian Cell Lines 
HEK293FT: Human embryonic kidney 293 (HEK293) cell line derivative that stably 
expresses the large T antigen of SV40 virus and has fast-growing specificity (Invitrogen 
R70007). 
HEK293T: Human embryonic kidney 293 (HEK293) cell line derivative that stably 
expresses the large T antigen of SV40 virus 
HCT116: Human colorectal carcinoma (HCT116) cell line that was derived from adult 
male, are positive for transforming growth factor-beta 1 (TGF beta 1) and beta 2 (TGF 
beta 2) expression (ATCC® CCL-247™) 
NK-92: IL-2 dependent human natural killer cell line, derived from 50 years old male 
malignant non-Hodgkin's lymphoma patient (ATCC® CRL 2407™). 
YTS: Derivative of YT cell line that was originally from a 15-year old male with acute 
lymphoblastic leukemia (ALL) were TCR-negative cells with NK cell activity (DSMZ 
ACC 434). 
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3.1.10. Plasmids and CRISPR Constructs 
The CRISPR constructs and plasmid those were used in this study are listed below. 
Table 6. List of CRISPR Constructs. All CRISPR constructs were cloned into 
LeGO-iG2p backbone 
Target Gene sgRNA Sequence 
AAVS1 Top CACCTAGGACAGGGATCACCGGGG  
Bottom AAACCCCCGGTGATCCCTGTCCTA 
CCDC124  Top CACCGGCGCAGCGTGTCCTCGATC  
Bottom AAACGATCGAGGACACGCTGCGCC 
DDX58  Top CACCGGGGTCTTCCGGATATAATCC  
Bottom AAACGGATTATATCCGGAAGACCCC 
IFIH1 Top CACCGCGAATTCCCGAGTCCAACCA  
Bottom AAACTGGTTGGACTCGGGAATTCGC 
PATZ1 Top CACCTGGCTGCTACACATACC  
Bottom AAACGGTATGTGTAGCAGCCA 
TLR3 Top CACCGTTCGGAGCATCAGTCGTTGA  
Bottom AAACTCAACGACTGATGCTCCGAAC 
    
Table 7. List of plasmids 
Plasmid Name Purpose of Use Source 
pMDLg/pRRE Virus production/packaging 
plasmid (Gag/Pol) 
Addgene (#12251) 
pRSV-REV Virus production/packaging 
plasmid (Rev) 
Addgene (#12253) 
pCMV-VSV-g Virus production/packaging 
plasmid (Env) 
Addgene (#8454) 
LeGO-G2 Lentiviral construct for GFP 
expression 
Kind gift from Prof. Boris 
Fehse of University Medical 
Center Hamburg-
Eppendorf, 
Hamburg, Germany 
LeGO-iG2-Puro Lentiviral construct for GFP 
expression 
with Puromycin resistance 
gene for selection 
Kind gift from Prof. Boris 
Fehse of University Medical 
Center Hamburg-
Eppendorf, 
Hamburg, Germany 
LeGO-iRFP670 Lentiviral construct for 
iRFP expression 
Kind gift from Adil 
Doğanay Duru of Nova 
Southeastern University, 
Florida, USA 
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3.1.11. Software, Computer-based Programs and Websites 
Table 8. List of used software, computer-based programs and websites. 
Software, Program and 
Website 
Company/Web Address Purpose of Use 
Addgene https://www.addgene.org/  Plasmid map and sequence 
information 
BD FACSDiva BD Biosciences Flow cytometry control 
software 
CLC Main Workbench v7.7  CLC bio  Constructing vector maps, 
restriction analysis, DNA 
sequencing analysis, DNA 
alignments, etc 
FlowJo v10  
 
Tree Star Inc. Analyzing raw flow 
cytometry data 
LightCycler 480 SW 1.5  ROCHE Analyzing qPCR results 
Office 365 Microsoft  Analytical calculations 
Origin 9.0 OriginLab Corp. Drawing graphs and plots 
3.2. Methods 
3.2.1. Bacterial Culture 
E. coli cells were cultured in LB media with ampicillin and grown at 37oC with 220 rpm 
shaking. For single colony picking, cells were spread on Petri dishes which had been 
prepared with ampicillin. Cell spread applied by glass beads and plates were placed into 
37oC incubator for overnight incubation. For long term storage of bacteria, single colonies 
grown overnight in liquid culture were further diluted 1:3 and were grown for another 3 
hours at 37oC with 221 rpm shaking. Bacteria were taken at log phase of growth and 
mixed with glycerol in 1 ml at final 10% (w/v) and preserved in cryotubes at -80oC. 
Macherey-Nagel Midiprep Kits were applied for DNA isolation according to 
manufacturer’s protocols. The final DNA concentration and purity were measured by a 
NanoDrop spectrophotometer. 
3.2.2. Mammalian Cell Culture 
Cell Thaw: Cells that are preserved in liquid nitrogen in cryotubes were taken on ice and 
slowly brought to RT. 15 ml tubes were prepared for each cell with 5 ml FBS. When the 
cell suspension was at RT, 1 ml frozen sample was pipetted very carefully into FBS, 
taking 2-3 minutes in total to avoid harming cells and dilute remnants of DMSO. The 
cells were then centrifuged at 300g for 5 minutes, and the supernatant was discarded. The 
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cell pellet was resuspended with complete media to reach 500,000-700,000 cells/ml 
concentration, and the cells were followed every day after thaw. 
Maintenance of Cell Lines: 293T, 293FT, and HCT116 cells were maintained in complete 
DMEM medium in sterile tissue culture flasks with filtered caps at an incubator set to 
37oC with 5% CO2. Cells were split when maximum 90% confluency was reached. The 
supernatant was discarded, and cells were washed with DPBS and trypsin was added to 
cell culture flasks and incubated in 37oC incubator with 5% CO2 for 5 minutes. Then the 
cells were resuspended in complete DMEM and split at 1:3 to 1:10 ratio and split every 
two days, never letting them reach full confluency. 
NK-92 and YTS cells were maintained in complete RPMI medium in sterile tissue culture 
flasks with filtered caps at an incubator set to 37oC with 5% CO2. Cells were kept at a 
density between 300,000 cells/ml to 1,000,000 cells/ml. 1000 U/ml human Interleukin-2 
(IL-2) was added every 48 hours for NK-92 cells. 
Cryopreservation: All types of cell lines were split one day before freezing to a 
concentration of 500,000 cells/ml for suspension cells and to a confluency of 30-40% for 
adherent cells. The next day, cells to be frozen were counted and at least 3x106 cells were 
frozen per vial. For each vial, cells were centrifuged at 300g for 5 minutes where 
supernatant was discarded, and the pellet was resuspended in 0.5ml FBS and incubated 
on ice for 15-20 minutes. In the meantime, 0.5 ml FBS with 12% DMSO was prepared 
fresh and incubated on ice. When the incubation was over, 0.5 ml cell suspension was 
mixed with 0.5 ml freezing medium to reach 6% DMSO in 1 ml. Cells were stored in 
cryotubes in -80oC for at least 24 hours, then in liquid nitrogen for long term storage. 
3.2.3. DNA Ladder 
 
Figure 5. DNA ladder that was used in electroporation experiments 
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3.2.4. Lentiviral Vector Production 
293FT cells were used as a transfection host in lentiviral vector production. 100 mm cell 
culture dishes were prepared by coating with 2 ml of filtered poly-L-lysine solution (0.1% 
w/v in H2O). After 8 min of incubation, leftover poly-L-lysine solution was removed, and 
dishes were rinsed with sterile ddH2O to dispose any residual of poly-L-lysine solution. 
When dishes get dried, 5x106 293FT cells were seeded to each dish and placed into 
incubator to be cultured overnight. Next morning, cells were transfected via calcium 
phosphate transfection method. For each dish, 7.5 μg of plasmid containing gene of 
interest, 3.75 μg of pMDLg/pRRE, 2.25 μg of pRSV-REV and 1.5 μg of phCMV-VSV-
G plasmids were combined and completed to 450 μL of mixture with sterile ddH2O. 50 
μL of 2.5 M CaCl2 was added to mixture slowly, and whole mixture was dissolved in 2X 
HBS buffer drop by drop while HBS buffer was being bubbled. During 15 minutes 
incubation of plasmids at room temperature, medium of the transfection dishes was 
replaced with fresh, 25 μM chloroquine containing DMEM-Glutamax. At the end of 
incubation of plasmids, plasmid mixture was distributed to transfection dishes dropwise, 
and dishes were placed to incubator. No later than 8-10 hours of incubation, chloroquine 
containing medium was discarded and fresh DMEM-Glutamax was given to the cells. 
Virus containing supernatants were collected in following 24 and 36 hours. The collected 
supernatant was filtered with 0.45 µm filters and stored in -80°C. 50 μL of aliquots from 
each gene of interest containing virus stored separately to determine virus titer by the 
transduction of 293FT cells. 
3.2.5. Virus Titration 
293FT cells were seeded in 24-well-plate with the concentration of 0.5x105 cells/well and 
plates were placed into the incubator to let cells to adhere onto the well bottom in 4-5 
hours. Then, serial concentrations of viral supernatant were given to cells in the presence 
of 8 μg/ml protamine sulfate. Titration plate was cultured for 16 hours, and supernatant 
was replaced with fresh DMEM. 48 hours after medium change, transduction efficiencies 
of different concentrations were obtained with flow cytometry. Depending on the 
fluorescent protein-expressing population percentage, multiplicity of infection (MOI) 
was calculated. 
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3.2.6. Lentiviral Transduction 
Suspension Cells: For each lentiviral transduction to generate knockout cells, 106 NK-92 
or YTS cells per T25 flask were seeded with an appropriate amount of virus supernatant 
in the presence of 8 μg/ml of protamine sulfate and 1.5 μM OXO. Cells were incubated 
at 37°C, 5% CO2 overnight and next day in the morning, cells were taken to sterile tubes 
and centrifuged at 300g for 5 minutes at room temperature to replace viral supernatant 
with fresh growth medium. 
For each lentiviral transduction to determine transduction efficiencies in different 
conditions, 2.5x105 NK-92 and YTS cells per well were seeded in 24-well-plates at 
specified MOI in the presence of 8 μg/ml Protamine Sulfate and 1000 U/ml IL-2 (only 
for NK-92 cells) for 6 hours. Depending on the experimental setup 3 μM BX795 or 1.5 
μM OXO was involved in lentiviral transduction. First 1 hour of 6 hours incubation took 
place in centrifuge at 1000g and 37°C, afterward plates were placed into incubators for 
the rest of the transduction period. After culturing cells in virus-containing media for the 
given time, plates were centrifuged for 45 minutes at 1000g with acceleration 9 and 
deceleration 4 for transductions done in 24-well-plates. Virus containing supernatant was 
completely removed and cells were cultured in their regular growth media for 72 hours 
before flow cytometry analysis. 
Adherent Cells: For each lentiviral transduction, 0.5x105 HCT116 and HEK293T cells 
per well were seeded in 12-well-plates for overnight culture. Next day in the morning, 
virus soup at specified MOI in the presence of 8 μg/ml Protamine Sulfate was introduced 
to the cells for 6 hours. Depending on the experimental setup 3 μM BX795 and/or 1.5 μM 
OXO was involved in lentiviral transduction. After culturing cells in virus-containing 
media for the given time, virus-containing supernatant was completely removed and cells 
were cultured in their regular growth media for 72 hours before flow cytometry analysis. 
3.2.7. Flow Cytometry 
For determining transgene expression, adherent cells were trypsinized and collected in 
PBS containing 0.1% FBS. Supernatants were discarded by centrifuge and cells carried 
on to analysis in PBS. 
For surface staining, NK-92 cells were washed once with PBS and stained with an 
appropriate amount of anti-CD56-APC on ice and in dark for 20 minutes. Cells were 
washed once more and carried on to analysis in PBS. 
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For cell-cycle analysis, suspension cells were set to 500.000 cell/ml a day ahead then 106 
cells of all cell types were taken for PI staining. Cell suspensions were centrifuged at 
300g for 5 minutes, and supernatants were discarded. Cells washed with PBS, and ice-
cold 70% ethanol (prepared previously and placed in -20oC) was added dropwise to fix 
cells for 30 minutes at +4oC. Cell suspensions were then centrifuged at 300g for 5 
minutes, and supernatants were discarded then washed with PBS and centrifugation 
applied again. Pellets were resuspended in RNAase A containing PBS and placed into 
incubator for 15 minutes incubation at 37oC. In the meantime, PI solution was prepared 
in PBS. At the end of incubation, cell suspensions were centrifuged at 300g for 5 minutes, 
and supernatants were discarded. PI solution was added onto pellets and tubes were 
incubated at room temperature for 15 minutes. After the incubation, more PBS was added 
to each tube and cells were carried on to flow cytometry analysis. 
3.2.8. PCR 
NEB Taq DNA Polymerase with Standard Taq (Mg-free) Buffer Kit was applied 
according to the manufacturer’s protocol. 
3.2.9. qRT-PCR 
RNA isolation: 3x106 cells were seeded for each type of cells, one day before the RNA 
isolation and the next day, all cells were lysed. Zymo Research RNA isolation Kits were 
applied according to manufacturer’s protocols. The final RNA concentration and purity 
were measured by NanoDrop spectrophotometer. 
cDNA Synthesis: RevertAid First Strand cDNA Synthesis Kit was applied according to 
manufacturer’s protocols. 
qPCR: LightCycler® 480 SYBR Green I Master Kit was applied according to 
manufacturer’s protocols and analysis was done according to 2-∆∆Ct method. 
3.2.10. Immunofluorescence Microscopy 
For microscopy experiments, coverslips were coated with a poly-L-lysine solution (0.1% 
w/v in H2O) for an hour at 37°C in 6-well-plates. The leftover poly-L-lysine solution was 
removed, and wells were rinsed with sterile ddH2O to dispose any residual of poly-L-
lysine solution. 2x106 NK-92 cells were seeded to each well then 6-well-plates were 
centrifuged at 900 rpm for 3 minutes and placed into 37°C and 44°C separately to cultured 
for an extra hour. At the end of incubation, plates were centrifuged again with same 
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conditions. After centrifugation, supernatant and unattached cells were removed, and 
wells were rinsed twice with PBS at room temperature. Ice-cold methanol (-20°C) was 
given to each well to fix cells and plates were incubated at +4°C for 10 minutes. When 
fixation was done, methanol was discarded, and wells were washed twice with PBS-T. 
Blocking solution was added to the wells to block and permeabilize the cells for 1 hour 
at room temperature on shaker. At the end of blocking, coverslips were stained primary 
antibody for 1 hour at room temperature or overnight at +4°C. Coverslips were washed 
with PBS-T three times for 5 minutes while gently shaking. Secondary antibody staining 
took place for 1 hour in the dark and coverslips were washed with PBS-T three times for 
5 minutes while gently shaking. DAPI staining solution was added onto the coverslips 
and incubated for 10 minutes then washed with ddH2O for 15 minutes. Coverslips were 
mounted to the slides with one drop of Mowiol and brought to confocal microscopy. 
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4. RESULTS 
4.1. The Use of Small Molecule Kinase Inhibitors in Lentiviral Gene Delivery 
The use of BX795 and OXO have been shown to reveal their role in multiple viral 
transductions. It has been reported that measles virus-mediated immunosuppression 
during viral infection can cause higher susceptibility of cells to secondary infections. 
Likewise, other virus types have shown side reactions as viral immunosuppression 
(Naniche and Oldstone 2000). To reveal the interference of this mechanism, we 
suppressed immunological pathways with small kinase inhibitors to compare 
immunosuppression effect on secondary viral transduction (Figure 6). 
2 4 6 8 10
0
5
10
15
20
25
30
35
40
45
50
55
2nd Tx Efficiency in Transduced Cells
%
 iR
FP
67
0
Day of 2nd Tx
 DMSO
 BX795
 OXO
 
Figure 6. The effect of kinase inhibitors on gene delivery tendency. NK-92 
cells were transduced with LeGO-G2 for 6 hr in the presence of DMSO, 
BX795 (3 µM) and OXO (1.5 µM) on day 0. Cells were introduced to LeGO-
iRFP670 as the secondary transduction on 2nd, 4th, 6th, 8th and 10th day after 
first transduction. Flow cytometry analysis was done on 3rd day after each 
transduction event. 
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In order to determine the effect of kinase inhibitors on further transductions, the 
proportion of double-positive cells to only GFP expressing cells were calculated. The 
cells that have been transduced with LeGO-G2 in the presence of inhibitors have shown 
similar efficiencies for 10 days period. On the other hand, absence of inhibitor in first 
transduction affects the antiviral behavior of transduced cells and decrease in gene 
delivery rates on these cells were observed. Our results indicate that if small molecule 
kinase inhibitors are not used in the first transduction, a subpopulation of cells that are 
more permissive to viral vector entry are targeted, and this reflects as increased 
transduction efficiency during second transduction, an effect that lasts for at least a week 
after the first transduction. On the other hand, the use of inhibitors during the first 
transduction removes this bias from the experiment. We concluded that utilization of 
kinase inhibitors during the first transduction is critical for lentiviral CRISPR/Cas9-based 
knockout of candidate genes in order to circumvent this bias.  
4.2. CCDC124 Expression in Studied Cell Lines 
CCDC124 expression was confirmed in all targeted cell lines via RT-PCR method 
(Figure 7). HeLa Fucci cells were included in PCR but excluded in further experiments. 
 
Figure 7. CCDC124 gene expression. a. HCT116 WT b. HCT116 p53-/- c. 
293T d. HeLa Fucci e. NK-92 f. YTS 
4.3. Generation of Knockout Cell Lines via the Lentiviral CRISPR/Cas9 System 
4.3.1. CRISPR/Cas9-mediated Gene Knock-out 
Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR, represents a highly 
effective and widely used RNA-guided genomic tool (Nair et al. 2019). Experimental 
CRISPR/Cas9 (CRISPR-associated nuclease 9) system can be designed to create double-
a     b      c      d       e      f 
CCDC124 
gene (134bp) 
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stranded breaks (DSBs) on DNA at specified point that is orchestrated by single-guide 
RNA (sgRNA) (Shalem et al. 2014). After the binding event between spacer sequence of 
sgRNA and target sequence of host DNA, Cas protein recognizes protospacer adjacent 
motif (PAM), which is next to target sequence and cleaves the target DNA (Pickar-Oliver 
and Gersbach 2019). Subsequent DSB repair mechanisms can follow two separate 
mechanisms, non-homologous end joining (NHEJ) and homology-directed repair (HDR) 
(Wyman and Kanaar 2006). Gene knockout application of CRISPR/Cas9 system relies 
on the error-prone NHEJ which usually ends up in insertions or deletions at the cleavage 
site (Khan, Yuen, and Luo 2019) that causes heterogeneity in NHEJ products (Waters et 
al. 2014).  The error in repair mechanism may lead loss of function in target protein or 
induces protein degradation because of damaged protein structure (Sherman and 
Goldberg 2001). Recent improvements on CRISPR/Cas9 system provide stable 
expression of sgRNA and Cas9 protein via using lentiviral vectors (Khan, Yuen, and Luo 
2019). Development of lentiviral CRISPR vectors facilitates knockout of specific target 
studies and promotes the future of CRISPR-based tool usage in clinic. 
4.3.2. Knockout Cell Line Generation 
The lentiCRISPR viruses of target genes were introduced to 106 cells in a T25 flask and 
cultured overnight in the presence of OXO and protamine sulfate. In the morning, virus-
containing supernatant was discarded and replaced with fresh medium. After 24 hours, 
Puromycin selection was started to obtain an enriched population of Cas9 expressing 
cells. Since lentiCRISPR constructs do not contain any fluorescent protein, Puromycin 
selection was maintained until knockout cells get synchronized with wild type cells. 
Besides that, as control, LeGO-iG2p virus with low MOI was also introduced to cell cells 
to follow Puromycin selection with GFP expression. When GFP expressing cells reach 
>90%, we accepted lentiCRISPR transduced cells as selected. Further experiments were 
conducted to confirm gene silencing.  
4.4. Characterization of Knockout Cell Lines 
4.4.1. Analysis of Target Gene Expression Levels 
CCDC124 mRNA levels of target cell lines were determined by qRT-PCR and 
normalized to GAPDH levels of each group. Our results show that following 
CRISPR/Cas9 modification, CCDC124 is significantly downregulated (Figures 8, 9, 10). 
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Figure 8. CCDC124 gene mRNA expression levels in HCT116 cell lines 
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Figure 9. CCDC124 gene mRNA expression levels in 293T cell lines 
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Figure 10. CCDC124 gene mRNA expression levels in NK-92 cell line 
4.4.2. Cell-Cycle Analysis of Knockout Cell Lines 
Cell-cycle progression of each cell group was analyzed by PI staining in flow cytometry. 
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Figure 11. DNA contents of HCT116 WT and CCDC124-/- cells 
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Figure 12. DNA contents of HCT116 p53- and p53-/- CCDC124-/- cells 
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Cell-cycle analysis revealed no significant differences between CCDC124-/- and WT 
cells, but both CCDC124-/- groups showed right-shift on the flow cytometer plot 
according to their control groups (Figures 11 and 12). We conclude that while cell-cycle 
is not affected, the total DNA content of the cells is increased possibly due to defects in 
cytokinesis and formation of multi-nucleated cells.  
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Figure 13. DNA contents of HEK293T WT and H60 mutant cells 
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Figure 14. DNA contents of NK-92 WT and CCDC124-/- cells 
For HEK293T (Figure 13) and NK-92 (Figure 14) cell lines, neither cell-cycle 
progression nor total cellular DNA content showed any difference between CCDC124-/- 
and control groups, indicating that CCDC124 does not cause a cytokinesis deficiency in 
these cell lines. 
4.4.3. Cell Size Analysis on Knockout Cell Lines 
Relative sizes of studied cells were observed by flow-cytometric light scattering 
measurements. Populations were first gated on FSC-A vs SSC-A plot, and single cells 
were gated FSC-A vs FSC-H plot. From single cells, FSC-A and SSC-A means of 
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populations were calculated by FlowJo software. Calculations showed that CCDC124-/- 
in HCT116, HEK293T, and NK-92 cells, increased the light scattering for both channels. 
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Figure 15. Cell Size Analysis 
For all cell types, CCDC124-/- groups showed an increase in their cell sizes compared to 
the control groups. While this effect is most pronounced in HCT116 cells, HEK293T and 
NK-92 cells also showed some increase in cell size (Figure 15). 
4.1. Antiviral Response of CCDC124-/- Cell Lines 
4.1.1. Combined Transduction with Kinase Inhibitors 
To estimate the antiviral behavior of cell lines and how it is affected by CCDC124, we 
introduced lentiviral vectors to these cells in three different MOIs, in the presence of small 
molecule kinase inhibitors. Unlike NK-92 cells, HCT116 cells responded to BX795 
negatively in terms of transduction efficiency while OXO showed similar enhancer effect. 
In a recent study, the off-target effect of BX795 during herpes simplex virus infection has 
been reported (Jaishankar et al. 2018). Inhibition of Akt pathway by BX795 blocks viral 
protein translation. In this specific cell line, HCT116, BX795 presence during viral 
transduction restricts transgene integration. 
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Figure 16. The efficiency of LeGO-G2 transduction to HCT116 cell lines in 
the presence of small kinase inhibitors 
When transduction efficiency of CCDC124-/- cells is compared to WT cells, a significant 
increase was observed in CCDC124-/- cells in all three MOIs whereas p53-/- cells did not 
show any significant difference compared to WT cells (Figure 16). Similar efficiencies 
were observed in double knockout cells, p53-/- and CCDC124-/- as it was in WT and 
single p53-/- cells. These results indicate that CCDC124 is involved in the antiviral 
response in HCT116 cells, but this effect is neutralized by p53 knockout. 
293T and H60 mutant responses against lentiviral vectors differ from the HCT116 cell 
line (Figure 17). Presence of BX795 did not show a significant difference when it is 
compared to DMSO presence during lentiviral transduction. However, OXO had negative 
effect on cells in terms of transduction efficiencies. Also, silencing CCDC124 gene in 
293T cells decreased the transduction efficiencies. 
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Figure 17. The efficiency of LeGO-G2 transduction to 293T cell lines in the 
presence of small kinase inhibitors 
In NK-92 cells, it is observed that CCDC124 gene had an extensive impact on gene 
delivery during lentiviral transduction (Figure 18). Flow cytometry results confirmed 
stable GFP expression for 14 days with high levels of GFP expressing population. 
Knocking out CCDC124 folded up transduction efficiencies ~40 times higher without 
any inhibitor even in low MOI. Small molecule kinase inhibitors enhanced the 
transduction efficiency up to 90%. 
 
Figure 18. The efficiency of LeGO-G2 transduction to NK-92 cell lines in the 
presence of small kinase inhibitors 
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4.1.2. Effect of Target Gene Knockout on Lentiviral Gene Delivery 
Further experiments conducted with CCDC124 overexpression plasmids and as a control 
iG2p since CCDC124 was cloned in iG2p backbone. Moreover, small molecule kinase 
inhibitors were excluded to investigate the role of CCDC124 only on lentiviral 
transduction. 
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Figure 19. The efficiency of LeGO-iRFP670 transduction to HCT116 cell 
lines 
Flow cytometry results show that prior introduction of lentiviral vector to HCT116 cells 
decrease efficiency in the second introduction of lentiviral vectors (Figure 19) even 
though small molecule kinase inhibitors had used in first transduction which is opposite 
effect that had been explained in section 4.1. Thus, CCDC124 overexpression had 
enhancing effect on transduction efficiency. 
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Figure 20. The efficiency of LeGO-iRFP670 transduction to 293T cell lines 
WT 293T cells did not show a significant difference in lentiviral transduction efficiencies 
when transduced second time (Figure 20). Additionally, CCDC124 overexpression did 
not change efficiencies as well in low MOIs however slight increase observed in MOI 5. 
H60 mutant cells responded to secondary viral transduction similar to HCT116 cells with 
reduced transduction efficiency, but CCDC124 overexpression in mutant cells recovered 
the transduction efficiencies and carried up to the levels as WT cells. 
YTS cell line experiments were conducted with iG2p, CCDC124-/-, and CCDC 
overexpressing cells against WT cells. CCDC124 expression of YTS cell lines was 
examined beforehand (Figure 21). Knockout and overexpression was confirmed and 
proceeded to further steps. Secondary viral transduction showed decrease in transduction 
efficiency (Figure 22). CCDC124-/- cells showed higher transduced population when it 
is compared to both WT and iG2p cells. For CCDC124 overexpressing cells, transduction 
values were lower than both WT and iG2p cells. 
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Figure 21. CCDC124 gene mRNA levels in studied YTS cells 
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Figure 22. The efficiency of LeGO-iRFP670 transduction to YTS cell lines 
4.1.3. The Role of CCDC124 Gene in Innate Antiviral Response of NK Cells 
Viral RNA sensing pathways and pattern recognition receptors have been explained 
previously. Among these, we targeted DDX58, IFIH1, and TLR3 to compare the antiviral 
response of CCDC124 in the absence of these genes separately. All knockout genes were 
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confirmed with qRT-PCR (Figure 23b). Lentiviral transduction of LeGO-iRFP670 
plasmid without any inhibitors has demonstrated the high impact of CCDC124 gene in 
antiviral defense mechanism of NK-92 cells (Figure 23a).  
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Figure 23. a) Lentiviral transduction efficiencies in knockout cells b) mRNA 
expression levels of separate genes. 
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4.1.4. CCDC124 and Stress Granules (SGs) in NK Cells 
Stress granule formation was examined in temperature-related stress conditions in WT, 
CCDC124-/- and CCDC124 overexpressing NK-92 cells (Figures 24, 25 and 26). Even 
though CCDC124 is significantly silenced, its expression still exists in CCDC124-/- 
populations and low CCDC124 expression is visible in CCDC124-/- cells while 
overexpressing cells show higher brightness with anti-CCDC124 staining. Stress granule 
formation is observed in all cell types that have been cultured under stress conditions but 
and overlaps with CCDC124 staining, indicating that CCDC124 is present in the stress 
granules of NK-92 cells. The cells that have been maintained in normal conditions did 
not show stress granule formation. 
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Figure 24. Stress granule formation in WT NK-92 cells 
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Figure 25. Stress granule formation in CCDC124-/- NK-92 cells 
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Figure 26. SG formation in CCDC124 over expressing NK-92 cells 
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5. DISCUSSION 
Viruses are pathogens that manipulate intracellular machinery of target cells and disrupt 
hosts antiviral defense mechanism (García-Sastre 2017). Retroviruses are RNA 
containing virions that evolved various mechanisms to counteract and subvert the 
immune system (Johnson 2019). One of the strategies to overcome immune effector 
mechanism that HIV-1 follows is hiding its genetic material in the viral capsid so that 
HIV-1 can escape from intracellular defense system until it integrates its viral RNA (Guha 
and Ayyavoo 2013). However, recognition of viral products after integration may activate 
or disrupt several antiviral pathways. To investigate the effect of this activation for 
secondary virus introduction, we set consecutive transduction experiments in the presence 
and absence of small molecule inhibitors. Inhibition of antiviral pathways with inhibitor 
administration during lentiviral transduction may catalyze the integration of viral genome 
without disturbing those pathways. As a result, we observed in the secondary lentiviral 
transductions that, once cells get activated by viral vectors, they acquire higher 
susceptibility to viral insertion, possibly due to a selection bias during the first 
transduction. Our results suggest that when virus disrupts antiviral pathways, 7-10 days 
are required for cell to recover intracellular mechanisms and behave like uninfected cells. 
On the contrary, inhibition of these pathways keeps intracellular mechanism to work 
correctly for further lentiviral transductions. According to these findings, we used the 
small molecule inhibitor, OXO, for knockout cell line generation in order to decrease 
lentiviral transduction efficiency bias for secondary lentiviral transductions. 
To confirm the silencing of CCDC124 gene, we checked mRNA levels of CCDC124 
gene in each group of cell lines. All types of cell lines were confirmed in terms of 
silencing to varying extents. Interestingly, we observed increased CCDC124 mRNA 
levels in p53 knockout HCT116 cell line. This consequence might be related to their 
common interacting genes such as APEX1 (Seemann and Hainaut 2005; Kristensen, 
Gsponer, and Foster 2012), VCP (Jethwa et al. 2018; Hülsmann et al. 2018b) and XPO1 
(Kırlı et al. 2015b; Santiago et al. 2013). All these three proteins are known to be related 
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to cell-cycle regulation, though their additional roles in intracellular mechanisms appear 
to be interfering with antiviral response and stress granule formation. The effect of the 
possible interaction between CCDC124 and p53 is also observed in lentiviral transduction 
results of HCT116 cell lines. Our first observation is increased transduction efficiency 
when CCDC124 is knocked out alone, however double knockout HCT116 cells, 
CCDC124-/- and p53-/-, show similar transduction efficiency with CCDC124 expressing 
cell lines. XPO1 is reported as the inhibitor of nuclear export of HIV-1 component Rev 
protein (Kırlı et al. 2015a). Another related gene, VCP, is identified as regulator of protein 
homeostasis and participator of intracellular membrane fusion under stress conditions 
(Hülsmann et al. 2018a). According to these findings, change in antiviral responses 
depending on the changing expression levels of CCDC124 and p53 genes may be related 
to interaction between CCDC124 and p53. 
Higher lentiviral transduction efficiencies are expected to be observed in the presence of 
small molecule inhibitors. In accordance with this, OXO showed a slight increase, but 
presence of BX795 have shown opposite effect. As it is discussed before, a recently 
published study (Jaishankar et al. 2018) reported the unexpected effect of BX795 in HSV-
1 infection. Jaishankar et al. suggested that inhibition of Akt pathway with BX795 also 
inhibits synthesis of viral proteins. This might be the reason for reduced levels of 
transduction efficiency in BX795 containing transduction events. 
Our further considerations about CCDC124 lacking cells are related to the DNA content 
of the cells and cell sizes. Dysfunctional cytokinesis has been reported as a result of 
CCDC124 knockout, which leads the formation of bi- and multinucleated cells 
(Telkoparan et al. 2013). Our results with HCT116 cell lines also confirms cytokinetic 
consequences of CCDC124 protein. 
Contrary to HCT116 lentiviral transduction results, CCDC124 knockout HEK293T cells 
have shown a decrease in transduction efficiency levels. Suppressor activity of 
transforming growth factor β-activated kinase 1 (TAK1) against transcription of hepatitis 
B virus in hepatoma cell lines have been reported previously (Pang et al. 2017). The same 
report demonstrated upregulated transcription levels of HBV during silenced or inhibited 
endogenous TAK1 expression. For further investigations, we recovered the expression 
levels of CCDC124 with CCDC124 overexpressing plasmid in H60 mutant cells and 
examined the transduction efficiencies compared to 293T and H60 mutant cells. 
Transduction levels showed that rescued CCDC124 raises the lentiviral transduction 
efficiency up to the same levels with control group. Characterization of HEK293T cell 
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lines showed that CCDC124 lacking cells are more abundant than control group without 
any increase in DNA content. 
Regarding these findings, we applied the same procedures to natural killer cell lines, NK-
92 and YTS. YTS cell lines showed expected results in lentiviral transduction efficiency, 
where CCDC124-/- YTS cells have higher viral genome integration and CCDC124 
overexpressing cells less integration compared to WT YTS cells. A drastic effect of 
CCDC124 knockout was observed in the NK-92 cell line. Lentiviral transduction 
efficiencies in CCDC124-/- NK-92 cells have shown significantly higher transduction 
levels compared to control group, while the addition of small molecule inhibitors has 
shown even higher transduction efficiencies. Characterization experiments did not show 
difference in DNA content between CCDC124-/- and control groups; however, 
CCDC124-/- NK-92 cells are slightly larger than WT NK-92 cells as in other cell lines. 
To compare the antiviral effect of CCDC124 protein in antiviral response, related proteins 
such as RIG-I, MDA5, and TLR3, were also knocked-out and lentiviral transduction 
efficiencies were investigated. Among all knockout cell lines CCDC124-/- group have 
shown highest transduction efficiencies compared to control groups which are wild type 
NK-92 cells and AAVS-/- cells. 
As it is mentioned previously, viral integration favors the dividing cells even if the 
lentiviral vectors can transduce both dividing and non-dividing cells. Therefore, it would 
be possible to expect the effect of CCDC124 on cytokinesis would decrease transduction 
efficiencies in knockout cells however these observations showed enhanced lentiviral 
transduction efficiencies which lead us to investigate the role of CCDC124 in stress 
granule related innate antiviral response. Confocal microscopy images of WT, 
CCDC124-/- and CCDC124 overexpressing NK-92 cells revealed that stress granule 
formation occurs under stress conditions but not in healthy maintained cells. Granular 
bodies are clearly visible in the cell groups that have been cultured under stress 
conditions. Merged images of different antibodies exhibit the co-localization of 
CCDC124 protein and stress granule marker G3BP1 only under stress conditions. 
However, stress granules were observed in all cell types that have expose to 44oC which 
means CCDC124 interacts with stress granules, but its role in stress granule formation is 
not clear yet. Additionally, further investigations with virus-related stress conditions and 
stress granule formation should be examined to understand CCDC124 role in innate 
antiviral response. 
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6. CONCLUSION 
This study indicated that CCDC124 protein is engaged in innate antiviral response. The 
use of small-molecule inhibitors in lentiviral transductions on NK-92 cell line showed 
significantly enhanced transduction values. On the other hand, off-target effect of these 
inhibitors has been demonstrated in different cancer cell lines which should be 
investigated in detail. Lentiviral transduction results in HCT116 cell lines showed the 
potential connection between CCDC124 and p53 proteins. CCDC124 relation in antiviral 
response was confirmed in HCT116 and NK cell lines. Consistent data in two natural 
killer cell lines, NK-92 and YTS, emphasizes the antiviral role of CCDC124 in innate 
immunity. Confocal microscopy results state that there is an interaction between 
CCDC124 and stress granules definitely however we need to further confirm its role in 
lentiviral stress granule formation. 
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Figure 30. The vector map of LeGO-G2 
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Figure 32. The vector map of iRFP670 
 
